Navigation Links
Medivation's Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimer's Disease Patients, Resulting in Reduced Caregiver Distress
Date:3/15/2008

t the entire one-year treatment period. Significantly fewer serious adverse events were reported in the Dimebon group than in the placebo group at 12 months (p=0.03).

Medivation is planning to initiate a second, confirmatory pivotal Phase 3 trial of Dimebon in mild-to-moderate Alzheimer's disease in the second quarter of 2008 with the goal of completing the trial and applying for U.S. and European marketing approval in 2010. The Company is also evaluating Dimebon in an ongoing Phase 2 clinical trial in mild-to-moderate Huntington's disease. Dimebon is an orally-available small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer's and Huntington's diseases, making it a potential treatment for these and other neurodegenerative diseases.

About Medivation

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company's strategy is to identify promising product candidates, to develop them in a rapid, cost-effective manner, and to seek development and/or commercialization partners as appropriate to complement its internal efforts. For more information, please go to http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding anticipated clinical and regulatory milestones, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. None of the Company's product candidates has been approved for sale, significan
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
2. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
3. Oxygen Relieves IBS and Constipation Symptoms in New Clinical Studies
4. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
5. New Data Shows Veramyst Effectively Treats Symptoms of Perennial Allergic Rhinitis
6. Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
7. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
8. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
9. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
10. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
11. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Mass. , Aug. 21, 2014  Decision ... COPD,  physicians in Brazil ... follow clinical guidelines and commonly prescribe long-acting beta-agonist ... although they do so within current severe cost/coverage ... (FDCs) that are expected to launch in these ...
(Date:8/21/2014)... 2014 /PRNewswire-iReach/ -- ScriptPro has been certified by ... Common Security Framework (CSF). According to Russ ... "We appreciate this rigorous, top-to-bottom audit. Security-minded customers ... certification signifies. Our business partners need to know ... CERTIFICATION PROCESS: ScriptPro,s internal security processes and controls ...
(Date:8/21/2014)... BreedIT Corp., (OTCQB: BRDT) ... worldwide license holder and distributor of highly sophisticated ... today is pleased to announce the formation of ... a leading Israeli medical Cannabis breeder. ... breeds of medical Cannabis to meet the requests ...
Breaking Medicine Technology:Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3ScriptPro Achieves HITRUST Certification 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4
... KVM Switches to be First Units to Sport New ... ... ATEN Technology, Inc., an,innovator of high-quality KVM (keyboard/video/mouse) and remote,connectivity ... the first LCD KVM switches to feature,product-protected antimicrobial nanocoating. The ...
... LA JOLLA, Calif., Sept. 10 TorreyPines,Therapeutics, Inc. ... its third,Phase I clinical trial for NGX267, in ... with schizophrenia (CIAS). The,compound, a functionally selective muscarinic ... when given orally to healthy male volunteers,once-daily for ...
Cached Medicine Technology:Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces 2Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces 3Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces 4TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia 2TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia 3
(Date:8/21/2014)... (PRWEB) August 21, 2014 Transvaginal ... Bard, Inc. continue to move forward in the ... Southern District of West Virginia, Bernstein Liebhard LLP ... August 14th, the Court has established new stipulated ... special handling, division, storage and preservation. (In re ...
(Date:8/21/2014)... care physicians in rural communities do not routinely ... to Penn State medical and public health researchers. ... have limited resources if they seek help., "Rural ... women," said Jennifer S. McCall-Hosenfeld, a primary care ... health sciences, Penn State College of Medicine. "However, ...
(Date:8/21/2014)... London, UK (PRWEB) August 21, 2014 ... from USD 15.6 billion in 2014 and reach USD ... during the forecast period. The drivers of such growth ... products, rising obese and diabetic population, and surging ageing ... costs of state-of-the-art wound care products. Region-wise, North America ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Lauren Collura, a ... the 2014 “Back to the Boardwalk” Facebook sweepstakes. Lauren, her ... a beautiful four-bedroom beachfront house in Lavallette beginning this Saturday. ... to the Boardwalk” sweepstakes. Last year, Horizon Blue Cross Blue ... communities after Superstorm Sandy and decided to make it a ...
(Date:8/21/2014)... THURSDAY, Aug. 21, 2014 (HealthDay News) -- In a ... that pregnant women avoid eating tuna due to concerns ... tuna, which is second only to shrimp as the ... encourage pregnant women to avoid all tuna," Jean Halloran, ... advocacy division of Consumer Reports, said in a news ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 3Health News:Primary care physicians can be critical resource for abused women in rural areas 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 3Health News:Consumer Reports Advises Pregnant Women to Avoid Tuna 2
... Nov. 5 Attorneys from Dallas, Rasansky Law Firm ... court on behalf of the mother of a 2-year-old girl who ... year ago. The lawsuit includes claims that the day care,s owners ... the child,s death from showing up on a state licensing database. ...
... is pleased to announce their standing in the latest ... quick, confidential performance ratings and comparisons of technology vendors, ... overall in their Q3 2009 Customer Satisfaction Industry Report. ... customer satisfaction score was the lowest ever reported by ...
... FRANCISCO, Nov. 5 Quantros, Inc., an industry leader ... point of care data surveillance solutions, today announced the ... ), a publicly traded company spun off from Cardinal ... were not disclosed. , This latest addition to ...
... Investments to ... ... nonprofit venture capital firm that invests in entrepreneurs who are building businesses to serve the ... Hill Eye and Laser Centre (UHEAL) in Kenya, both of which provide advanced eye care ...
... study finds, , THURSDAY, Nov. 5 (HealthDay News) -- What ... a good night,s sleep come more easily. , A study ... the odds of having disturbed sleep in the seven years ... years before they stopped working. , Sleep improvements probably had ...
... , WATSONVILLE, Calif., Nov. 5 Nordic Naturals ... especially for pregnant women to ensure adequate DHA, an ... for the new mother and developing baby. Prenatal DHA ... the leading non-profit organization in the United States that ...
Cached Medicine News:Health News:The Rasansky Law Firm Announces Dallas Day Care Death Lawsuit; State Investigation Finds Evidence of Negligence at Woodbridge Day School 2Health News:ChemSW Rated Top Vendor Overall for Customer Satisfaction in Q3 2009 by VendorRate 2Health News:Quantros Acquires MediQual(TM) From CareFusion Corporation 2Health News:Quantros Acquires MediQual(TM) From CareFusion Corporation 3Health News:Acumen Fund Announces Two Investments Providing Advanced Eye Care Services in India and Kenya 2Health News:Acumen Fund Announces Two Investments Providing Advanced Eye Care Services in India and Kenya 3Health News:Acumen Fund Announces Two Investments Providing Advanced Eye Care Services in India and Kenya 4Health News:Without Job Stress, Retirees Sleep Better 2Health News:Nordic Naturals Professional Exclusive Division Introduces Prenatal DHA An Omega-3 Fatty Acid Supplement for Pregnant Women 2
... AST (GOT) powder reagent once reconstituted offers ... liquid stability to help maximize laboratory productivity, ... turnaround time. The patented technology of the ... long shelf life and stability once reconstituted ...
LCD chart display...
... are extremely delicate and if repairs are ... can easily be damaged beyond repair and ... , On the other hand, with conscientious ... have a virtually indefinite lifespan. The very ...
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
Medicine Products: